In the past years, considerable energy has been put into evaluating the safety of cirmtuzumab in clinical trials (phase I and II) [112] in hematological B cell malignancies, where it had been identified as a tumor marker, then extending its use to ROR1-expressing solid tumors, such as breast cancer. The gene discussed is ROR1; the disease is neoplasm.